FindTrial
Sign In

Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

Single Patient Expanded Access Treatment Plan (EAP; Also Known As A Compassionate Use Plan) To Provide Patients Access To The Investigational Product Narsoplimab

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04247906
Enrollment
Unknown
Registered
2020-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

Brief summary

The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their respective physicians.

Interventions

DRUGNarsoplimab

Sponsors

Omeros Corporation
Lead SponsorINDUSTRY
Impatients N.V. trading as myTomorrows
CollaboratorINDUSTRY

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Patient (adult or pediatric) must have undergone allogeneic or autologous hematopoietic stem cell transplant (HSCT) * Patient must be capable of understanding an informed consent form (ICF) or the parent or legal guardian of the patient is able to understand and sign a written ICF prior to the initiation of any treatment procedures. * Patient must have HSCT- TMA defined as having thrombocytopenia and evidence of microangiopathic hemolytic anemia.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026